AbbVie Inc.

02/28/2020 | Press release | Distributed by Public on 02/28/2020 20:31

AbbVie Provides Update from Phase 3 Study Evaluating VENCLEXTA® (venetoclax) in Combination with Low-Dose Cytarabine in Newly-Diagnosed Patients with Acute Myeloid Leukemia (AML)